Artal Group S.A. Sage Therapeutics, Inc. Transaction History

Artal Group S.A.

$1.58 Billion
Q2 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$40.65 - $59.54 $10.2 Million - $14.9 Million	-250,000 Reduced 33.33%	500,000 $23.5 Million
Q3 2022 Nov 14, 2022	BUY	$32.28 - $43.27 $9.68 Million - $13 Million	300,000 Added 66.67%	750,000 $29.4 Million
Q2 2022 Aug 11, 2022	SELL	$27.52 - $37.99 $8.26 Million - $11.4 Million	-300,000 Reduced 40.0%	450,000 $14.5 Million
Q1 2022 May 12, 2022	SELL	$30.71 - $45.71 $7.68 Million - $11.4 Million	-250,000 Reduced 25.0%	750,000 $24.8 Million
Q2 2021 Aug 13, 2021	BUY	$54.88 - $79.29 $19.2 Million - $27.8 Million	350,000 Added 53.85%	1,000,000 $56.8 Million
Q1 2021 May 14, 2021	BUY	$70.65 - $96.76 $17.7 Million - $24.2 Million	250,000 Added 62.5%	650,000 $48.7 Million
Q4 2020 Feb 11, 2021	BUY	$58.41 - $89.06 $10.4 Million - $15.8 Million	177,700 Added 79.94%	400,000 $34.6 Million
Q3 2020 Nov 13, 2020	SELL	$41.13 - $62.45 $481,221 - $730,665	-11,700 Reduced 5.0%	222,300 $13.6 Million
Q2 2020 Aug 14, 2020	SELL	$25.95 - $43.15 $3.01 Million - $5.01 Million	-116,000 Reduced 33.14%	234,000 $9.73 Million
Q1 2020 May 14, 2020	BUY	$26.15 - $77.24 $5.23 Million - $15.4 Million	200,000 Added 133.33%	350,000 $10.1 Million
Q2 2019 Aug 09, 2019	BUY	$157.85 - $183.09 $3.95 Million - $4.58 Million	25,000 Added 20.0%	150,000 $27.5 Million
Q1 2019 May 10, 2019	BUY	$89.33 - $163.65 $2.23 Million - $4.09 Million	25,000 Added 25.0%	125,000 $19.9 Million
Q1 2018 May 10, 2018	BUY	$152.15 - $192.33 $3.8 Million - $4.81 Million	25,000 Added 33.33%	100,000 $16.1 Million
Q4 2017 Feb 09, 2018	SELL	$60.72 - $167.34 $4.55 Million - $12.6 Million	-75,000 Reduced 50.0%	75,000 $12.4 Million
Q3 2017 Nov 08, 2017	BUY	$61.4 - $88.52 $9.21 Million - $13.3 Million	150,000	150,000 $9.35 Million

Others Institutions Holding SAGE

# of Institutions

218

Shares Held

48.2M

Call Options Held

854K

Put Options Held

195K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $415M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.

Account